Royal Bank of Canada
LAB icon

Royal Bank of Canada’s Standard BioTools LAB Stock Holding History

Royal Bank of Canada’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
235
-9,190
-98% -$11.1K ﹤0.01% 7424
2025
Q4 		$12K Buy
9,425
+2,838
+43% +$3.81K ﹤0.01% 6326
2025
Q3 		$8K Sell
6,587
-18,537
-74% -$24.3K ﹤0.01% 6570
2025
Q2 		$30K Buy
25,124
+2,941
+13% +$3.26K ﹤0.01% 6126
2025
Q1 		$24K Sell
22,183
-8,210
-27% -$11.5K ﹤0.01% 5857
2024
Q4 		$53K Sell
30,393
-98
-0.3% -$183 ﹤0.01% 5668
2024
Q3 		$59K Buy
30,491
+1,879
+7% +$3.68K ﹤0.01% 5618
2024
Q2 		$50K Sell
28,612
-29,768
-51% -$72.8K ﹤0.01% 5661
2024
Q1 		$158K Buy
58,380
+6,241
+12% +$15.1K ﹤0.01% 4878
2023
Q4 		$115K Buy
52,139
+1,904
+4% +$4.06K ﹤0.01% 5532
2023
Q3 		$146K Sell
50,235
-13,144
-21% -$34.4K ﹤0.01% 5083
2023
Q2 		$122K Buy
63,379
+3,129
+5% +$6.18K ﹤0.01% 5172
2023
Q1 		$117K Sell
60,250
-1
-0% -$2 ﹤0.01% 5052
2022
Q4 		$70K Sell
60,251
-66
-0.1% -$81 ﹤0.01% 5701
2022
Q3 		$66K Buy
60,317
+82
+0.1% +$124 ﹤0.01% 5581
2022
Q2 		$96K Sell
60,235
-4,681
-7% -$11.6K ﹤0.01% 5358
2022
Q1 		$233K Sell
64,916
-11,183
-15% -$38.6K ﹤0.01% 4949
2021
Q4 		$299K Buy
76,099
+27,869
+58% +$130K ﹤0.01% 4944
2021
Q3 		$317K Sell
48,230
-18,397
-28% -$121K ﹤0.01% 4730
2021
Q2 		$410K Buy
66,627
+49,891
+298% +$267K ﹤0.01% 4455
2021
Q1 		$76K Sell
16,736
-63,811
-79% -$350K ﹤0.01% 5634
2020
Q4 		$483K Buy
80,547
+61,632
+326% +$405K ﹤0.01% 4171
2020
Q3 		$141K Buy
18,915
+18,672
+7,684% +$129K ﹤0.01% 4768
2020
Q2 		$1K Sell
243
-1,266
-84% -$4.41K ﹤0.01% 6447
2020
Q1 		$3K Buy
1,509
+809
+116% +$2.66K ﹤0.01% 6190
2019
Q4 		$2K Hold
700
– – ﹤0.01% 6557
2019
Q3 		$3K Sell
700
-212
-23% -$1.67K ﹤0.01% 6200
2019
Q2 		$12K Buy
+912
New +$11.6K ﹤0.01% 5962
2018
Q4 		– Sell
-562
Closed -$4K – 6941
2018
Q3 		$4K Buy
562
+544
+3,022% +$3.87K ﹤0.01% 6344
2018
Q2 		$0 Buy
18
+6
+50% +$34 ﹤0.01% 6656
2018
Q1 		$0 Sell
12
-230
-95% -$1.51K ﹤0.01% 6576
2017
Q4 		$1K Sell
242
-2,418
-91% -$13.2K ﹤0.01% 6395
2017
Q3 		$13K Buy
2,660
+2,504
+1,605% +$10.5K ﹤0.01% 6174
2017
Q2 		$1K Sell
156
-1,044
-87% -$4.95K ﹤0.01% 6407
2017
Q1 		$7K Sell
1,200
-839
-41% -$5.32K ﹤0.01% 6103
2016
Q4 		$14K Buy
2,039
+2,013
+7,742% +$12.6K ﹤0.01% 5950
2016
Q3 		$0 Buy
26
+25
+2,500% +$230 ﹤0.01% 6497
2016
Q2 		$0 Sell
1
-6
-86% -$56 ﹤0.01% 6452
2016
Q1 		$0 Sell
7
-95
-93% -$685 ﹤0.01% 6522
2015
Q4 		$1K Sell
102
-14,120
-99% -$139K ﹤0.01% 6478
2015
Q3 		$115K Buy
14,222
+9,144
+180% +$144K ﹤0.01% 4697
2015
Q2 		$123K Buy
+5,078
New +$160K ﹤0.01% 4708
2014
Q1 		– Sell
-4,071
Closed -$156K – 6020
2013
Q4 		$156K Buy
4,071
+2,067
+103% +$60.9K ﹤0.01% 4316
2013
Q3 		$44K Buy
+2,004
New +$39.4K ﹤0.01% 4864

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Royal Bank of Canada's LAB Position: Q1 2026 in Review

Royal Bank of Canada reduced its Standard BioTools (LAB) stake by 98% in Q1 2026, selling an estimated $11.1K and leaving 235 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7424.

Royal Bank of Canada first reported a position in LAB in Q3 2013 and has held it in 44 quarters since. The position peaked at $483K in Q4 2020. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Royal Bank of Canada held 235 shares of Standard BioTools worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 9,190 Standard BioTools shares in Q1 2026, an estimated $11.1K.
  • Standard BioTools made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7424 holding.
  • Royal Bank of Canada first reported a position in Standard BioTools in Q3 2013 and has held it in 44 quarters since.
  • Royal Bank of Canada's Standard BioTools position peaked at $483K in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.